Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway
about
Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCManagement of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistanceDiscovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Emission tuning of fluorescent kinase inhibitors: conjugation length and substituent effects.The quest to overcome resistance to EGFR-targeted therapies in cancer.miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-MetCombination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinomaRationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancerToward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Liquid biopsy: monitoring cancer-genetics in the blood.Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancerRedundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumorsThe long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis.EGFR: The Paradigm of an Oncogene-Driven Lung CancerBMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin ReceptorEGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.Non-small-cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase inhibition through immediate adhesion-related responses.Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutationElevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancerActivation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancerBypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surfaceGallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.The role of afatinib in the management of non-small cell lung carcinoma.
P2860
Q26745427-27429D07-14F9-4248-AAF8-C6AE1B086206Q26747276-F61D4A88-97A1-4641-8726-2A5481E4966DQ26775379-10C77284-F9D3-4053-9FC5-D9682D96CD84Q27852553-1388EF08-D8F7-425D-9C30-BAED0E0E7507Q27853013-619BD170-22C5-4467-82C0-2ACF2F433045Q28394310-A67A3315-0BCE-4A68-9A27-84A022224854Q33601653-CEBC8D62-8AB3-4970-A7DE-FF1EF271DFD0Q33725573-BAF2B4ED-FC83-4CE3-8E00-16B007CB3D24Q33725976-1B421D47-352E-4026-923E-FCFE76E6AF72Q33774131-D67DF3B5-2373-45AA-8A3A-2D4EB5DBA984Q33875560-F784A596-077D-44A4-9202-35F1B86314F1Q34156513-0118D039-CAE0-4869-B7D6-9C322E1C3542Q34260686-6E9F2131-DCEF-4E97-8FCB-0CC263D70CC3Q34336988-38F57A01-B84C-4B65-A775-A63BE1347638Q34356149-BD87116A-A010-4C5E-B2BB-E08289FFF258Q34392733-DCAC4D39-C140-478B-966E-DCE86243E051Q34704781-C89FC194-82EC-4F4D-8A86-A2FA3535049EQ35226507-8CA7C0FC-2A11-4173-8C83-5B841B52E42DQ35568803-D2F6BD37-E6BE-49BB-B89F-C74B600D5BD1Q35604127-5E2568B8-FC0C-4E16-94EF-7714F38A27B9Q35619241-EEAFC698-451F-4ED8-BBBB-6E161531A1DDQ35940305-A16CDD37-3C77-49AD-BF03-0CE5E9720319Q35994416-EDD276CB-1110-4C98-BBCE-56BEC84463ABQ36104980-983253FB-1100-4C75-9B8D-3C411804BDA9Q36387216-39A2A69D-766D-4BCB-B2B5-E968D056650FQ36687288-4206EFC6-765B-47D5-8805-D8C4900B0C9DQ36688968-BB455D96-7D0E-47B3-ADA5-FF2BC9EA35C0Q36759183-9A853393-A2CF-40E9-80D4-CB8314BD4A40Q36775204-C4139B28-D1F6-47C8-9B95-8F8C80B8CC0BQ36939668-86AFB78F-103E-4732-A3F8-ECB8EFDC4277Q36962642-0B67CD20-A488-41BD-8824-236A60DE165BQ36970403-EAD6A537-D452-4F60-80BF-B11DFD5FC98CQ37046462-BBC5300D-01C6-4CA6-9A4B-656D80BBF6E7Q37099888-2508338C-4EC0-48D0-B12A-6D599CB3361DQ37225463-B8B34BC7-E753-4993-A0AB-48FB9E2F3DC6Q37421439-2F1F92B9-1C84-4ADC-ABA4-D234078F85A2Q37634419-FF780393-0FAA-4527-847A-A76072BE940EQ37686308-D1F4ECBC-962E-456A-898C-9232156A373DQ37688123-AF7D683B-6F5E-4A77-BB3B-2947930CE63EQ38132282-4A4B6BF3-674F-4702-A453-87ED14808385
P2860
Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Resistance to irreversible EGF ...... sm involving the IGF1R pathway
@en
Resistance to irreversible EGF ...... m involving the IGF1R pathway.
@nl
type
label
Resistance to irreversible EGF ...... sm involving the IGF1R pathway
@en
Resistance to irreversible EGF ...... m involving the IGF1R pathway.
@nl
prefLabel
Resistance to irreversible EGF ...... sm involving the IGF1R pathway
@en
Resistance to irreversible EGF ...... m involving the IGF1R pathway.
@nl
P2093
P2860
P1433
P1476
Resistance to irreversible EGF ...... sm involving the IGF1R pathway
@en
P2093
Alexis B Cortot
Claire E Repellin
Dalia Ercan
James G Christensen
Kreshnik Zejnullahu
Marzia Capelletti
Nathanael S Gray
Takeshi Shimamura
P2860
P304
P356
10.1158/0008-5472.CAN-12-2066
P407
P577
2012-11-19T00:00:00Z